<DOC>
	<DOCNO>NCT01419535</DOCNO>
	<brief_summary>Background : - Metabolic syndrome name give group factor tend occur together . These risk factor include central obesity ( extra weight around middle body ) high blood pressure blood sugar level . They also include low level HDL ( `` good cholesterol '' ) high triglyceride level . A person say metabolic syndrome three risk factor . People metabolic syndrome increase risk type 2 diabetes , stroke , heart disease . - Cortisol , hormone produce adrenal gland , important regulator metabolism . People central obesity metabolic syndrome may higher normal cortisol level body regulate properly . Abnormal cortisol level may play important role metabolic syndrome . Mifepristone drug block cortisol . Researchers interested study effect metabolic syndrome . Objectives : - To study effect short-term mifepristone treatment metabolic syndrome . Eligibility : - Men Women 35 70 year age overweight obese , abnormal glucose triglyceride level . Design : - Participants screen physical exam medical history . They also blood urine test . - Participants admit metabolic unit National Institutes Health Clinical Center first 3 day study : - Day 1 : Body measurement ( height , weight , waist , hip , neck ) blood pressure test . Also , 24 hour regular blood draw 24-hour urine collection monitor regular daily cortisol level . - Day 2 : Glucose/insulin infusion test measure blood sugar level . - Day 3 : Infusion cortisol-like compound regular blood draw 3 hour evaluate cortisol metabolize . - At end Day 3 , participant receive mifepristone look-alike capsule take 7 day home . - After 7 day , participant return metabolic unit repeat Day 1 Day 2 study procedure . They continue take mifepristone . - One week second set study test , participant return brief physical exam blood test . - The study procedure repeat 6 8 week , study drug .</brief_summary>
	<brief_title>Mifepristone Metabolic Syndrome</brief_title>
	<detailed_description>The hormone cortisol key regulator metabolism influence use glucose ( sugar ) fat fuel . Persistently increase cortisol level , Cushing syndrome , lead obesity , type 2 diabetes mellitus lipid abnormality include elevated triglyceride level low high-density lipoprotein ( HDL ) level . These disorder also present patient without Cushing syndrome , suggest cortisol may involve pathogenesis . Mifepristone cortisol-like drug block cortisol action body . It reverse lipid abnormality , diabetes obesity Cushing syndrome patient effect condition test patient without syndrome . The long-term aim clinical trial evaluate ability mifepristone reverse improve glucose intolerance , dyslipidemia , hypertension weight gain . An initial 7-day prospective , randomize , placebo-controlled , crossover study propose look effect short-term administration oral mifepristone placebo glucose intolerance . Given human data available effect mifepristone insulin sensitivity , pilot study 15 subject . Data study use design large trial evaluate long-term effect blood pressure weight , well glucose triglyceride control . Overweight obese subject abnormal glucose tolerance undergo two treatment randomize order , include mifepristone mouth look-alike inert tablet mouth . Each treatment study include two three day baseline test repeat seven day treatment . Treatments separate least six eight week . The test include blood drawing , urine collection , administration glucose insulin vein , cortisol-like material evaluate metabolism cortisol relate hormone , corticosterone .</detailed_description>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Men woman 35 70 year age 2 . Subjects overweight obese , BMI range 25 37 kg/m2 . 3 . Subjects either impair fast glucose ( great equal 100 mg/dL ) 2hour glucose value great equal 140 mg/dl oral glucose tolerance test ( OGTT ) . OR Mild diabetes define patient Hba1c le equal 7 % medication ( dietcontrolled ) stable dose metformin hypoglycemic agent great equal 3 month study entry . 4 . Willing able comply study requirement . EXCLUSION CRITERIA : 1 . Pregnancy lactation 2 . Diabetes require pharmacologic treatment . Diagnosis diabetes base 2011 American Diabetes Association guideline : Hba1c great equal 6.5 % , fast plasma glucose great equal 126 mg/dl , 2hour glucose great equal 200 mg/dl OGTT , random blood glucose great equal 200 mg/dl along classic symptom hyperglycemia ( 34 ) 3 . Uncontrolled hypertension ( blood pressure great equal 180/110 mmHg ) 4 . Current unstable medical condition include clinically significant impaired cardiac function ( Stage III IV Cardiac failure ) , cardiac ischemia , severe respiratory insufficiency require oxygen therapy assess history and/or physical exam 5 . Liver function test ( ALT , AST ) 3times upper normal limit 6 . Severe renal impairment ( creatinine clearance &lt; 30 ml/min ) 7 . Evidence human immunodeficiency virus ( HIV ) base history physical examination and/or know positive HIV antibodies 8 . Evidence hepatitis C base history physical examination and/or know positive hepatitis C ( HCV ) antibody 9 . History hemorrhagic disorder anticoagulant 10 . History endometrial cancer , endometrial hyperplasia , unexplained vaginal bleeding , endometrial thickness great 6 mm 11 . Change dose lipidlowering medication ( include HMG CoA inhibitor , fibrates , niacin , ezetemibe , overthecounter fish oil supplement ) within one month study entry study period 12 . Current administration medication know strong CYP3A4 inhibitor include ketoconazole , itraconazole , erythromycin 13 . Use herbal supplement grapefruit juice within 14 day study drug initiation 14 . Use medication dietary supplement inihibit induce CYP3A4 activity within 14 day study drug initiation 15 . Use oral , injectable , inhaled glucocorticoid megestrol past six month 16 . Use estrogencontaining hormone therapy 17 . Potential pseudocushing state : depression intake &gt; 2 alcoholic drink day . Subjects screen depression use wellvalidated physician health questionnaire9 ( PHQ9 ) score cutoff great equal 10 moderate depression ( 35 ) . 18 . Subjects actively diet weight loss program 19 . Midnight salivary cortisol &gt; 100 ng/dl two separate occasion 20 . Untreated thyroid dysfunction ( TSH Free T4 within normal range ) . If abnormal screening lab , repeat confirm due lab error nonthyroidal illness . 21 . Moderate severe anemia ( hemoglobin &lt; 10 g/dl ) 22 . Blood donation 500 ml within one month prior study enrollment 23 . Subjects prolong QTc interval electrocardiogram 24 . Unable give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 16, 2016</verification_date>
	<keyword>Metabolism</keyword>
	<keyword>Cortisol</keyword>
	<keyword>Hypercortisolism</keyword>
	<keyword>Glucose Intolerance</keyword>
</DOC>